Lexicon Pharmaceuticals (LXRX) H.C. Wainwright 26th Annual Global Investment Conference 2024 summary

Strategic direction and operational focus

• Implemented Lead to Succeed strategy, prioritizing high-value projects and conserving $40 million in operating expenses for the next year.

• Doubling down on first- or best-in-class assets in large markets with unmet needs, focusing on cardiometabolic and neuroscience disorders.

• Streamlined commercial and medical presence to maximize value with a focused footprint.

• Refocused resources to indications where the company can be the first and only therapy.

• Driving value for all stakeholders by targeting areas with significant white space.

Pipeline progress and clinical milestones

• Sotagliflozin (Zynquista) resubmitted for type 1 diabetes with chronic kidney disease; AdCom scheduled for October 31, PDUFA date December 20, 2024.

• Phase 3 SONATA study of sotagliflozin in hypertrophic cardiomyopathy is actively enrolling.

• LX9211 phase 2b study in diabetic peripheral neuropathic pain on track for top-line data in H1 2025.

• LX9851, an oral obesity candidate, in pre-IND studies with IND submission targeted for mid-2025.

• Continued promotion of INPEFA for heart failure, focusing on experienced prescribers.

Market opportunities and differentiation

• Zynquista could become the only SGLT inhibitor approved for type 1 diabetes with CKD, addressing a 400,000-patient U.S. market.

• Sotagliflozin offers a unique, once-daily oral option for hypertrophic cardiomyopathy, with a pragmatic phase 3 design targeting both obstructive and non-obstructive forms.

• LX9211 aims to redefine neuropathic pain and spasticity care, with a placebo-controlled phase 2b study showing significant pain score improvements.

• LX9851 targets obesity with an oral, incretin-independent mechanism, showing weight and lean mass benefits in preclinical models.

• All pipeline medicines are oral, supporting a 'pipeline in a pill' approach for multiple indications.